660P - A retrospective study of chemoradiotherapy (CRT) versus chemotherapy (CT) as adjuvant treatment for localized gastric cancer (LGC)

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gastric Cancer
Surgical Oncology
Radiation Oncology
Presenter Daniel Girardi
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors D.D.M. Girardi1, G.C. Pereira1, M. Negrão1, M.A. Lima1, M.M. Felizola1, R.N. Fogace1, F.C. Capareli1, J. Sabbaga2, P.M. Hoff3
  • 1Oncology, Instituto do Câncer do Estado de São Paulo, 01246-000 - São Paulo/BR
  • 2Oncologia Clínica, ICESP - Instituto do Câncer do Estado de São Paulo, 01246-000 - Sao Paulo/BR
  • 3Oncologia Clinica, ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo/BR



Treatment of LGC consists of surgical resection followed by adjuvant treatment. Indeed either CRT or CT regimen have shown benefit in survival outcomes versus observation. However, there are few data comparing these approaches. This study aims to compare the toxicity and efficacy of CRT versus CT.


This retrospective study included consecutive patients (pts) with LGC treated at Instituto do Cancer do Estado de Sao Paulo (ICESP) from 2012-2015. CRT (group 1) was based on the INT-0116 regimen and CT (group 2) consisted of a platinum and fluoropyrimidine doublet. Treatment choice was based on physician's preference. Toxicity was evaluated for every cycle. Overall survival (OS) analysis was performed by Kaplan Meier.


A total of 309 pts were evaluated, 227 in group 1 and 82 in group 2 (chemotherapy regimen: XELOX 78; XP 4). Groups were very similar regarding pts characteristics. Median age at diagnosis was 58.7y and 56.5y with male predominance (59.9% and 58.5%). Most pts presented with ECOG 0/1 (92% and 92,3%), in clinical stage III (53,3% and 69,5%). Type of surgical procedure was also well balanced with D2 node dissection been performed in 73,1% and 79,3% and R0 resection in 91,2% and 87,8% of pts. More prevalent grade 3 and 4 toxicities in groups 1 and 2 respectively were: nausea and vomiting (9.2% vs 4.9%), asthenia (9.3% vs 2.4%), mucositis (4.4% vs 1.2%), neutropenia (37.8% vs 20.9%), febrile neutropenia (3.9% vs 0%); anemia (4.3% vs 6.1%), thrombocytopenia (2.6% vs 4.9%), neuropathy (0 vs 2.4%) and hand-foot syndrome (0.4% vs 2.4%). Two grade 5 toxicities (febrile neutropenia and anemia) had occurred in group 1. Dose reductions were more common in group 2 (11% vs 52.4%). Treatment discontinuation rates were similar (35.7% vs 35.4%), with toxicity being the most common cause (48.2% vs 41.4%). After median follow up of 21 months (group 1) and 16.5 months (group 2), there was no difference in OS (2-year OS: 69.1% vs 65.2%).


CT appears to be equally effective and less toxic than CRT as adjuvant treatment for LGC and may be a reasonable option for centers with limited access to radiotherapy.

Clinical trial identification

Legal entity responsible for the study

Instituto do Câncer do Estado de São Paulo


Instituto do Câncer do Estado de São Paulo


All authors have declared no conflicts of interest.